Compare Motorola Solutions Inc (MSI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Motorola Solutions (MSI) trades at $449.01, up 0.64% today, with a neutral technical signal. The company shows strong fundamentals: revenue grew to $11.68B in 2025, net income margin is 17.44%, and it has beaten EPS estimates for three consecutive quarters. Recent news includes a $1.5B acquisition of D-Fend Solutions and a $139M public safety contract in Louisiana, highlighting growth in defense and security segments. Cash flow from operations is robust at $2.84B, though net cash flow was negative due to significant investing activities.

Outlook is positive given analyst consensus of a $525.86 price target and 70.59% buy ratings, supported by record backlog and strategic acquisitions. Risks include high valuation multiples (P/E 35.38) and increased debt levels, with net cash flow turning negative in 2025-2026. The stock offers growth potential in mission-critical solutions but faces execution risks from integration of recent buys and competitive pressures.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.